Turning cancer resistance into vulnerability
Targeted Therapy for Relapsed & Refractory Cancers
We engineer small molecules designed to exploit metabolic vulnerabilities precisely when standard therapies fail. Our Mission: Delivering cures for patients who have run out of options.
They support us
Our Technology - A metabolic trap
Cancer cells are addicted to proliferation and die when starved
Healthy cells simply pause and survive
Meet Our Complementary Team
Management Team
Guillaume Dubreuil
Co-founder & CEO
Guillaume Dubreuil
20+ years expertise inBusiness Development
Xavier Morelli
Co-founder & CSO
Xavier Morelli
CNRS Research Director (DRCE)25+ years expertise in Drug Discovery
Didier Pez
Co-founder & COO
Didier Pez
25+ years expertise inBiotech Drug Development
Name Placeholder
Co-founder & CCO
Name Placeholder
Driving commercial strategy and strategic partnerships to bring our precision therapeutics to patients globally.
Scientific Advisory Board
V. Asnafi
MD, PhD
Head of the Onco-Hematology laboratory and co-directs the "Normal and Pathological Lymphoid Differentiation Team" Institut Necker Enfants Malades
N. Vey
MD, PhD
Managing Director at the Institut Paoli-Calmettes (IPC), Professor of Hematology at Aix-Marseille University
C. Halfon-Domenech
MD, PhD
Head of the Pediatric immunohematology from Institut d’hématologie et d’oncologie pédiatrique (IHOPe)
F. Bellamy
MD, PhD
Medicinal Chemistry and Preclinical Development within the pharmaceutical industry and start-up companies
P. Dubreuil
MD, PhD
Doctor in Immunology Recognized expert in signal transduction pathways and kinase biology
The Science is Ready
- check_circleTargeting unmet medical needs in pediatric and adult oncology.
- check_circleSafe targeted therapy.
- check_circleSpeed up recovery while preserving the patient’s immune system.
The Team is Ready
- check_circleHigh-growth market potential with next-gen small molecules.
- check_circleRobust pipeline designed to maximize long-term ROI.
- check_circleexclusive worldwide license (PATENT: WO 2023/135330A1)
Together, let's transform the future of Leukemia
Investors, partners, and clinicians — let's build the future of precision oncology together.